TLSI vs CNMD vs NVCR vs ATRC vs ABT

For growth investors, TriSalus Life Sciences, Inc.

(TLSI) is the stronger pick with 53. 4% revenue growth year-over-year, versus 4. 6% for Abbott Laboratories (ABT). Abbott Laboratories (ABT) offers the better valuation at 11. 4x trailing P/E (15. 4x forward), making it the more compelling value choice. Analysts rate TriSalus Life Sciences, Inc. (TLSI) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Abbott Laboratories (ABT) is the cheapest at 11.

4x versus CONMED Corporation at 25. 2x. On forward P/E, CONMED Corporation is actually cheaper at 8. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CONMED Corporation wins at 0. 23x versus Abbott Laboratories's 0. 51x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Abbott Laboratories (ABT) delivered a total return of -17.

9%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ABT returned +166. 6% versus TLSI's -57. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

22β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 894% more volatile than ABT relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TriSalus Life Sciences, Inc.

(TLSI) is pulling ahead at 53. 4% versus 4. 6% for Abbott Laboratories (ABT). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to -64. 6% for CONMED Corporation. Over a 3-year CAGR, TLSI leads at 53. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus -154. 3% for TriSalus Life Sciences, Inc. — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABT leads at 16. 3% versus -59. 7% for TLSI. At the gross margin level — before operating expenses — TLSI leads at 84. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, CONMED Corporation (CNMD) is the more undervalued stock at a PEG of 0. 23x versus Abbott Laboratories's 0. 51x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CONMED Corporation (CNMD) trades at 8. 4x forward P/E versus 428. 7x for AtriCure, Inc. — 420. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TLSI: 135. 4% to $10. 50.

In this comparison, ABT (2.

5% yield), CNMD (2. 1% yield) pay a dividend. TLSI, NVCR, ATRC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

22), 2. 5% yield, +166. 6% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +166. 6%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TLSI is a small-cap high-growth stock; CNMD is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock; ABT is a mid-cap deep-value stock. CNMD, ABT pay a dividend while TLSI, NVCR, ATRC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.